Preoperative risk stratification using 18F-FDG PET/CT in women with endometrial cancer;Präoperative risikostratifizierung mittels 18F-FDGPET/CT bei frauen mit endometriumkarzinom

NuklearMedizin

Volumn 50, Issue 5, 2011, Pages 204-213

  Lee, H J ^a   Ahn, B C ^a   Hong, C M ^a   Song, B I ^a   Kim, H W ^a   Kang, S ^a   Jeong, S Y ^a   Lee, S W ^a   Lee, J ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

Endometrial cancer; FDG PET CT; Preoperative risk stratification; SUV

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER INVASION; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; ENDOMETRIUM CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH VESSEL; MAJOR CLINICAL STUDY; MYOMETRIUM; PREOPERATIVE EVALUATION; PROGNOSIS; RISK ASSESSMENT; TUMOR VOLUME; UTERINE CERVIX;

ENDOMETRIAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80053504612     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0375-10-12     Document Type: Article

References (35)

1. 18F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 2008; 35: 246-252.
2. Amant F, Moerman P, Neven P et al. Endometrial cancer. Lancet 2005; 366: 491-505.
3. 18F-FDG PET: histo-logic and immunohistochemical tissue analysis. J Nucl Med 2001; 42: 9-16.
4. Bakkum-Gamez JN, Gonzalez-Bosquet J, Laack NN et al. Current issues in the management of endome-trial cancer. Mayo Clin Proc 2008; 83: 97-112.
5. Bar-Shalom R, Yefremov N, Guralnik L et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003; 44: 1200-1209.
6. 18F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med 2003; 44: 1044-1050.
7. 18F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging 2002; 29: 1132-1139.
8. Benedetti Panici P, Basile S, Maneschi F et al. Systematic pelvic lymphadenectomy vs. no lymphade-nectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008; 100: 1707-1716.
9. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med 2009; 50: 88-99.
10. Benjamin EG. NCCN Clinical Practice Guidelines in Oncology: Uterine neoplasm. National Comprehensive Cancer Network 2010; www.nccn.org/professionals/physician_gls/f_guidelines.asp.
11. Brown RS, Leung JY, Fisher SJ et al. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med 1995; 36: 1854-1861.
12. 18F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings. Eur J Nucl Med Mol Imaging 2008; 35: 1081-1088.
13. 18F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancer. Eur J Nucl Med Mol Imaging 2010; 37: 1467-1473.
14. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 2007; 48 (Suppl 1): 78S-88S.
15. Franchi M, Ghezzi F, Riva C et al. Postoperative complications after pelvic lymphadenectomy for the surgical staging of endometrial cancer. J Surg Oncol 2001; 78: 232-240.
16. Heudel P, Cimarelli S, Montella A et al. Value of PET-FDG in primary breast cancer based on histo-pathological and immunohistochemical prognostic factors. Int J Clin Oncol 2010; 15:588-593.
17. Hickeson M, Yun M, Matthies A et al. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mo Imaging 2002; 29: 1639-1647.
18. Hidaka T, Kato K, Yonezawa R et al. Omission of lymphadenectomy is possible for low-risk corpus cancer. Eur J Surg Oncol 2007; 33: 86-90.
19. Jemal A, Siegel R, Ward E et al. Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225-249.
20. Kessler RM, Ellis JR Jr, Eden M. Analysis of emission tomographic scan data: limitations imposed by resolution and background. J Comput Assist Tomogr 1984; 8: 514-522.
21. Kitajima K, Murakami K, Yamasaki E et al. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer. Ann Nucl Med 2008; 22 103-109.
22. Kitchener H, Swart AM, Qian Q et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009; 373: 125-136.
23. Larson DM, Johnson K, Olson KA. Pelvic and para-aortic lymphadenectomy for surgical staging of en-dometrial cancer: morbidity and mortality. Obstet Gynecol 1992; 79: 998-1001.
24. Morrow C P, Bundy BN, Kurman RJ et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991; 40: 55-65.
25. 18F-FDG PET correlates with histologi-cal grade in endometrial cancer. International Journal of Gynecological Cancer 2010; 20: 110-115.
26. Pecorelli S, Benedet JL, Creasman WT, Shepherd JH. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 1999; 64: 5-10.
27. 18F]FDG PET/CT in preoperative staging. Nucl Med Com-mun 2010; 31: 506-512.
28. Saga T, Higashi T, Ishimori T et al. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Ann Nucl Med 2003; 17: 197-203.
29. Signorelli M, Guerra L, Buda A et al. Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage en-dometrial cancer: detection of pelvic nodal meta-stases. Gynecol Oncol 2009; 115: 231-235.
30. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007; 48: 932-945.
31. 18F-FDG PET of breast cancer: presentation of a simple model using a single reference point for time corrections of tumor SUVs. J Nucl Med 2011; 52: 18-23.
32. Suzuki R, Miyagi E, Takahashi N et al. Validity of positron emission tomography using fluoro-2-deo-xyglucose for the preoperative evaluation of en-dometrial cancer. Int J Gynecol Cancer 2007; 17: 890-896.
33. Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 2004; 45: 1431-1434.
34. 18F-FDG PET. J Nucl Med 2009; 50: 1598-1604.
35. Yasumizu T, Ogawa K, Kato J. Comparison of the clinicopathological characteristics of premenopau-sal and postmenopausal endometrial carcinomas: analysis of endocrinologically evaluated cases. Jpn J Clin Oncol 1996; 26: 152-156.